A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Farletuzumab (Primary) ; Carboplatin; Doxorubicin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Morphotek
  • Most Recent Events

    • 08 Feb 2017 Planned End Date changed from 1 May 2020 to 1 May 2021.
    • 08 Feb 2017 Planned primary completion date changed from 1 Aug 2018 to 1 May 2019.
    • 03 Oct 2016 Planned End Date changed from 1 Aug 2019 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top